Nonsystemic treatment of metastatic tumors of the liver—a review

Lee, Yeu‐Tsu N.

doi:10.1002/mpo.2950040302

Cited by 13 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mori et al [22] reported a selective destruction of the tumor without damage to the normal liver after ligation of the hepatic artery for metastatic gastric carcinoma. The response to surgical ligation is temporary, in part due to the formation of collateral circulation that may occur almost instantaneously [23].…”

Section: Hepatic Artery Embolization (Hae)mentioning

confidence: 99%

Recurrent cancer and metastases

et al. 1982

View full text Add to dashboard Cite

show abstract

Section: Hepatic Artery Embolization (Hae)mentioning

confidence: 99%

Recurrent cancer and metastases

et al. 1982

View full text Add to dashboard Cite

show abstract

Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver

Patt

Mavligit

Chuang

et al. 1980

Cancer

View full text Add to dashboard Cite

The response rate of metastatic colorectal carcinoma confined to the liver to HA1 of FUDR alone is at the range of 50% and to mitomycin C by hepatic arterial infusion (HAI) at the range of 35%. Mitomycin C was added to FUDR by continuous infusion and given by HA1 to 12 patients with colorectal cancer confined to the liver. Catheters were placed subselectively in the hepatic artery, and infusion continued for five to six days when the catheter was removed. Cycles were repeated every 30 days. Chemotherapy consisted of mitomycin C 15 mg/m' administered on day 1 followed by FUDR 100 mg/m2 by continuous infusion daily for five days. Response to treatment was evaluated by serial determinations of plasma CEA and by imaging techniques consisting of a computerized tomography, sonography , and radio-nuclide scanning of liver as well as by angiography. In 2 patients, complete remission was achieved; in 4 patients a 75% and in another 4 patients a 50% decrease in liver metastasis was observed, while 2 patients had stable disease. Thus, a response rate of 83% with a median duration of six to seven months was achieved. The median survival of these patients was 16 months. Eight of the 12 patients have failed previous, i.v. 5-FU containing regimens. Complications related to 45 treatment cycles were the following: catheter displacement in 11.1%, an intimal tear, usually in the hepatic artery in 4.4%, gastric ulcerations in 5.4%, and septicemia in 2.7% of the cycles. In addition, aneurysmal dilation of the hepatic artery occurred in 4 patients (8.8% of the treatment cycles), all of whom continued treatment. Chemotherapy-related complications included primarily thrombocytopenia and stomatitis. Mitomycin C + FUDR by hepatic arterial infusion is an effective treatment for colorectal carcinoma metastatic to the liver. The high response rate justifies the adjuvant treatment of Dukes class C colon cancer patients with this treatment Cancer 46:261-265, 1980. ETASTATIC COLORECTAL CARCINOMA confined to M the liver, refractory to intravenous chemo-therapy, will respond to hepatic arterial infusion (HAI) of chemotherapy.' Promising results have been reported with a combination of HA1 of floxuridine (FUDR) and hepatic r a d i a t i ~ n , ' ~ and HA1 of C. parvum and ~hemotherapy.~ When metastases are localized, partial liver resection is a valid consideration .Io The increased sensitivity of liver metastases to drugs administered intraarterially is the result of their ex-* Giora M. Mavligit, MD is a recipient of a PHS Career Development Award CA-00130-04. posure to higher concentrations of chemotherapy. Inactivation of these agents by the liver parenchyma occurs ~ubsequently.~ The blood leaving the liver through the hepatic veins contains lower drug levels ,* exposing normal tissues to lower drug concentrations and thereby lessening toxic side effects. Since mitomycin C (MTC) and FUDR have both activity in colon carcinoma3 and are inactivated by the liver,5 the combination of these chemotherapeutic agents exposes the liver metastases to very...

show abstract

Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells

Okuno

Takagi

Nakamura

et al. 1986

Cancer

View full text Add to dashboard Cite

Nonspecific tumoricidal effectors, called lymphokine-activated killer (LAK) cells, can be induced from the tumor-bearer's spleen in vitro. The adoptive transfer of such LAK cells to a patient with unresectable hepatoma was performed in this study. About 2.4 X 10(9) LAK cells generated from the autologous spleen were adoptively transferred to the patient via hepatic arterial catheter. Signs of toxicity encountered with LAK cell infusions comprised chills and fever only. Chemical studies of hepatic, renal, and hematologic parameters were normal; pulmonary function studies revealed no changes after infusion. With the transfer of LAK cells, serum alpha-fetoprotein (AFP) levels were markedly decreased and ascitic fluid retention was transiently reduced. Though the therapeutic effect was transient, these trials offered hope for a new therapeutic approach to unresectable hepatoma. Further, the availability of large amounts of recombinant interleukin-2 (rIL-2) may now make widespread use of this approach possible.

show abstract

Nonsystemic treatment of metastatic tumors of the liver—a review

Cited by 13 publications

References 69 publications

Recurrent cancer and metastases

Recurrent cancer and metastases

Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver

Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells

Contact Info

Product

Resources

About